Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brigitte Dreno

Showing results (191-200 of 213) with videos related to

Pageof 22
Sort By:
Cancer|October 23, 2019
Quality-of-life assessment in French patients with metastatic melanoma in real lifeMarguerite Kandel, Stéphane Dalle, Aurélie Bardet, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
Nature Medicine|May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceClaus Garbe, Reinhard Dummer, Teresa Amaral, et al.
The Lancet. Oncology|January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international surveyAxel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2022
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022Marie-Léa Gauci, Cynthia Aristei, Jurgen C Becker, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and preventionAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Pageof 22

Showing results (191-200 of 213) with videos related to

Sort By:
Pageof 22
Cancer|October 23, 2019
Quality-of-life assessment in French patients with metastatic melanoma in real lifeMarguerite Kandel, Stéphane Dalle, Aurélie Bardet, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
The Journal of Investigative Dermatology|January 30, 2009
A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized studyPascal Joly, Jean-Claude Roujeau, Jacques Benichou, et al.
Nature Medicine|May 16, 2023
Neoadjuvant immunotherapy for melanoma is now ready for clinical practiceClaus Garbe, Reinhard Dummer, Teresa Amaral, et al.
The Lancet. Oncology|January 5, 2025
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international surveyAxel Hauschild, Claus Garbe, Paolo Antonio Ascierto, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The New England Journal of Medicine|June 7, 2011
Improved survival with vemurafenib in melanoma with BRAF V600E mutationPaul B Chapman, Axel Hauschild, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2022
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022Marie-Léa Gauci, Cynthia Aristei, Jurgen C Becker, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and preventionAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.
Pageof 22